Last reviewed · How we verify

Usual dose treatment of Tandospirone

Sumitomo Pharma (Suzhou) Co., Ltd. · FDA-approved active Small molecule

Usual dose treatment of Tandospirone is a 5-HT1A receptor agonist Small molecule drug developed by Sumitomo Pharma (Suzhou) Co., Ltd.. It is currently FDA-approved for Generalized anxiety disorder, Major depressive disorder.

Tandospirone is a serotonin 1A (5-HT1A) receptor agonist that enhances serotonergic neurotransmission in the central nervous system.

Tandospirone is a serotonin 1A (5-HT1A) receptor agonist that enhances serotonergic neurotransmission in the central nervous system. Used for Generalized anxiety disorder, Major depressive disorder.

At a glance

Generic nameUsual dose treatment of Tandospirone
SponsorSumitomo Pharma (Suzhou) Co., Ltd.
Drug class5-HT1A receptor agonist
Target5-HT1A receptor
ModalitySmall molecule
Therapeutic areaPsychiatry/Neurology
PhaseFDA-approved

Mechanism of action

Tandospirone selectively binds to and activates 5-HT1A receptors, which are G-protein coupled receptors involved in mood regulation and anxiety control. By acting as a partial agonist at these receptors, it increases serotonergic activity in brain regions associated with anxiety and depression, leading to anxiolytic and antidepressant effects. This mechanism is distinct from selective serotonin reuptake inhibitors (SSRIs) as it directly activates the receptor rather than blocking reuptake.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Usual dose treatment of Tandospirone

What is Usual dose treatment of Tandospirone?

Usual dose treatment of Tandospirone is a 5-HT1A receptor agonist drug developed by Sumitomo Pharma (Suzhou) Co., Ltd., indicated for Generalized anxiety disorder, Major depressive disorder.

How does Usual dose treatment of Tandospirone work?

Tandospirone is a serotonin 1A (5-HT1A) receptor agonist that enhances serotonergic neurotransmission in the central nervous system.

What is Usual dose treatment of Tandospirone used for?

Usual dose treatment of Tandospirone is indicated for Generalized anxiety disorder, Major depressive disorder.

Who makes Usual dose treatment of Tandospirone?

Usual dose treatment of Tandospirone is developed and marketed by Sumitomo Pharma (Suzhou) Co., Ltd. (see full Sumitomo Pharma (Suzhou) Co., Ltd. pipeline at /company/sumitomo-pharma-suzhou-co-ltd).

What drug class is Usual dose treatment of Tandospirone in?

Usual dose treatment of Tandospirone belongs to the 5-HT1A receptor agonist class. See all 5-HT1A receptor agonist drugs at /class/5-ht1a-receptor-agonist.

What development phase is Usual dose treatment of Tandospirone in?

Usual dose treatment of Tandospirone is FDA-approved (marketed).

What are the side effects of Usual dose treatment of Tandospirone?

Common side effects of Usual dose treatment of Tandospirone include Dizziness, Headache, Nausea, Somnolence, Insomnia.

What does Usual dose treatment of Tandospirone target?

Usual dose treatment of Tandospirone targets 5-HT1A receptor and is a 5-HT1A receptor agonist.

Related